---
document_datetime: 2023-09-21 18:57:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/xtandi-epar-all-authorised-presentations_en.pdf
document_name: xtandi-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7794182
conversion_datetime: 2025-12-24 23:56:01.560211
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging     | Pack size    |
|------------------|-------------------|------------|-----------------------|---------------------------|-------------------------|--------------|
| EU/1/13/846/001  | Xtandi            | 40 mg      | Capsule, soft         | Oral use                  | blister (PVC/PCTFE/alu) | 112 capsules |
| EU/1/13/846/002  | Xtandi            | 40 mg      | Film-coated tablet    | Oral use                  | blister (PVC/PCTFE/alu) | 112 tablets  |
| EU/1/13/846/003  | Xtandi            | 80 mg      | Film-coated tablet    | Oral use                  | blister (PVC/PCTFE/alu) | 56 tablets   |